FDA’s phasing out of Animal Testing and Adoption of New Approach Methodologies

At Scendea we are actively monitoring the NAM and evolving regulatory landscape, including existing and future NAM databases and any precedents, to guide our clients on incorporating NAMs in their development to derisk, reduce costs, and expedite their paths to clinic. 

For more information on the status of NAMs, in the US and globally, Scendea has authored a white paper on the topic. To find out how Scendea can assist you in navigating the challenges and opportunities of NAMs in your development journey, get in touch...